CN1481876A - Medication for virus hepatitis and hepatocirrhosis - Google Patents
Medication for virus hepatitis and hepatocirrhosis Download PDFInfo
- Publication number
- CN1481876A CN1481876A CNA031354785A CN03135478A CN1481876A CN 1481876 A CN1481876 A CN 1481876A CN A031354785 A CNA031354785 A CN A031354785A CN 03135478 A CN03135478 A CN 03135478A CN 1481876 A CN1481876 A CN 1481876A
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- liver
- mushroom
- viral hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 206010019799 Hepatitis viral Diseases 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 title description 9
- 201000001862 viral hepatitis Diseases 0.000 claims abstract description 11
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 8
- 241000222336 Ganoderma Species 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 14
- 241000208340 Araliaceae Species 0.000 claims description 8
- 241000190633 Cordyceps Species 0.000 claims description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 8
- 235000008434 ginseng Nutrition 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 claims description 8
- 241000272525 Anas platyrhynchos Species 0.000 claims description 6
- 108010052008 colla corii asini Proteins 0.000 claims description 6
- 235000015177 dried meat Nutrition 0.000 claims description 6
- 102000002322 Egg Proteins Human genes 0.000 claims description 5
- 108010000912 Egg Proteins Proteins 0.000 claims description 5
- 241000287828 Gallus gallus Species 0.000 claims description 5
- 241000209140 Triticum Species 0.000 claims description 5
- 235000021307 Triticum Nutrition 0.000 claims description 5
- 240000000920 Typhonium flagelliforme Species 0.000 claims description 5
- 210000004681 ovum Anatomy 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 6
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 241000208688 Eucommia Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000021388 linseed oil Nutrition 0.000 abstract 1
- 239000000944 linseed oil Substances 0.000 abstract 1
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 description 9
- 230000007882 cirrhosis Effects 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 208000007386 hepatic encephalopathy Diseases 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 4
- 102000006395 Globulins Human genes 0.000 description 4
- 108010044091 Globulins Proteins 0.000 description 4
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000180649 Panax notoginseng Species 0.000 description 3
- 235000003143 Panax notoginseng Nutrition 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 210000003240 portal vein Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 240000000599 Lentinula edodes Species 0.000 description 2
- 235000001715 Lentinula edodes Nutrition 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 239000009526 Fructus Akebiae Substances 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 208000024283 Gingival haemorrhages Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 244000303847 Lagenaria vulgaris Species 0.000 description 1
- 235000009797 Lagenaria vulgaris Nutrition 0.000 description 1
- 241001582888 Lobus Species 0.000 description 1
- 241000283956 Manis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008918 xingnaojing Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The medicine for treating viral hepatitis and hepatocirrhosis is prepared with red sage, mushroom, glossy ganoderma, aweto, eucommia bark, flax oil and other nine kinds of Chinese medicinal materials. It has high curative effect, wide indication range, no toxicity, no side effect and no damage to liver.
Description
Technical field:
The present invention is relevant with the medicine of treatment viral hepatitis, liver cirrhosis disease.
Background technology:
Natural drug treatment liver cirrhosis disease and chronic hepatitis diseases such as utilization Chinese herbal medicine are studied for many years always and are explored.The traditional Chinese medical science to the understanding of liver cirrhosis mainly is: due to illness do not heal for a long time, irritability lose to be dredged, venation discord, damp and hot strongly fragrant for a long time, liver spleen two wounds, qi depression to blood stasis, retention of water-damp in the body, liver body are lost and supported for a long time withered hardening.Treatment to be supporting spleen, and through clinical verification Chinese medicine, as: Radix Bupleuri, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, PINGDIMU, Radix Pseudostellariae, the Rhizoma Atractylodis Macrocephalae, Semen Coicis, Rhizoma Dioscoreae, the Radix Astragali, Herba Taraxaci, Pericarpium Arecae, moxibustion Endothelium corneum plus-minus.Epistaxis, gingival hemorrhage, red tongue add the Radix Rehmanniae, Rhizoma Imperatae, Radix Notoginseng, Radix Paeoniae Rubra, Cortex Moutan.Hematemesis, have blood in stool, add Rhizoma Bletillae powder, the water transfer of Radix Notoginseng powder equivalent is taken.Hepatosplenomegaly adds Squama Manis, Fructus Akebiae, rhizoma sparganic, Rhizoma Curcumae, reuses Radix Salviae Miltiorrhizae.Enlarged abdomen such as drum, add Pericarpium Arecae, Lagenaria siceraria(Molina) Standl.var.depressa Ser., Herba Lobeliae Chinensis, Herba Verbenae, Herba Lycopi, Rhizoma Alismatis or use Pill for Relieving Ascites.Hepatic coma adds cow-bezoar bolus for resurrection, Zhibao Dan, XINGNAOJING.Low albumen can be used conditioning albumen such as Colla Corii Asini, Placenta Hominis, the Rhizoma Atractylodis Macrocephalae, Radix Codonopsis, Carapax et Plastrum Testudinis, Rhizoma Polygonati.Raise immunity, most with the kidney invigorating, Qi-tonifying drug: Radix Ginseng, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Radix Morindae Officinalis, Rhizoma Polygonati, Herba Epimedii, Cordyceps, Fructus Lycii, Radix Polygoni Multiflori, Herba Cistanches etc.Suppress immunologic function, based on heat-clearing and toxic substances removing, as Herba Hedyotidis Diffusae, Rhizoma Polygoni Cuspidati etc.Fibrosis mostly is blood circulation promoting and blood stasis dispelling, collateral dredging softening the hard mass medicine, as Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Flos Carthami, Radix Notoginseng, stir-baked SQUAMA MANITIS, Carapax Trionycis, rhizoma sparganic, Rhizoma Curcumae, Herba Sidae Rhombifoliae granule, Radix Et Rhizoma Rhei
Worm ball, shell liver softening tablet etc.
Different symptoms classification therapeutic purposes screening in the natural medicinal materials of above-mentioned a large amount of animals and plants, combination Pharmaceutical composition, of a great variety, though the guideline difference, different characteristics and the curative effect that all has separately of usage.
These medicines to be to attack, and make liver in damaged condition strengthen the metabolism burden, the medicine infringement liver and the immunologic function of heavy dose of, chronicity, in case drug withdrawal, the state of an illness " bounce-back " amount are greatly, even the state of an illness increases the weight of.Wherein some medicine has toxicity, side effect.
Summary of the invention:
The objective of the invention is in order to overcome above deficiency, provide a kind of nontoxic, have no side effect, harmless to liver, therapeutic effect is good, the wider treatment viral hepatitis of subject range, the medicine of liver cirrhosis disease.
The object of the present invention is achieved like this:
The medicine that the present invention treats viral hepatitis, liver cirrhosis disease comprises following component by weight:
The Radix Ginseng Rubra 1～4
Mushroom 5～9
Ganoderma 3～8
Cordyceps 1～3
Du. secondary 3～7
Oleum lini 6～10 can replace mushroom with the Lentinus Edodes of artificial culture, Lentinus Edodes etc., and its effect is basic identical.
Above-mentioned treatment viral hepatitis, the medicine of liver cirrhosis disease comprise following component by weight:
The Radix Ginseng Rubra 1～4
Mushroom 5～9
Ganoderma 3～8
Cordyceps 1～3
The Cortex Eucommiae 3～7
Oleum lini 6～10
Radix Scrophulariae 2～6
Fructus Jujubae 4～8
Huai wheat 5～10
Radix Glehniae 6～10
Colla Corii Asini 2～6
Ovum Gallus domesticus Flavus 2～5
Semen juglandis 6～10
Typhonium flagelliforme (Lodd.) Blume 1～5
Duck dried meat 6～12 therapeutic effect are good.
Above-mentioned treatment viral hepatitis, the medicine of liver cirrhosis disease comprise following component by weight:
The Radix Ginseng Rubra 2
Mushroom 8
Ganoderma 4
Cordyceps 2
Du. secondary 4
Oleum lini 8.5
Radix Scrophulariae 4
Fructus Jujubae 5
Huai wheat 8
Radix Glehniae 8
Colla Corii Asini 4
Ovum Gallus domesticus Flavus 3.5
Semen juglandis 8.5
Typhonium flagelliforme (Lodd.) Blume 2
Duck dried meat 10
Therapeutic effect is good.
The present invention treats Radix Ginseng Rubra in the medicine of viral hepatitis, liver cirrhosis disease, Ganoderma, Cordyceps, Ovum Gallus domesticus Flavus can strongly invigorating primordial QI, raise immunity; Pester antibiotic, be good for the stomach and spleen Typhonium flagelliforme (Lodd.) Blume dissipating blood stasis hemostasis, subduing swelling and relieving pain; Radix Glehniae, Radix Scrophulariae, YIN nourishing is supported liquid; The analgesic detoxification of oleum lini, suppressing the hyperactive liver be pleasant, control the skin Pruritus; Colla Corii Asini, Fructus Jujubae, semen juglandis tonifying the kidney to consolidate the essence, benefiting qi and nourishing blood, increase albumin, erythrocyte etc.; Duck dried meat YIN nourishing is supported lung, inducing diuresis to remove edema; Huai wheat, the Cortex Eucommiae, semen juglandis have the raising body immune function, short sugar, protein metabolism, contraction coronary vasodilator, cholesterol reducing effect; Modern medicine thinks that oleum lini, semen juglandis are rich in the necessary aminoacid of multiple human body such as linolenic and linoleic, cooperates the synthetic plant animal protein of duck dried meat.Medicine of the present invention is grown liquid with the strengthening the body resistance in the theory of Chinese medical science, yin nourishing, and raising and adjustment body's immunity combine together.For a large amount of hypertrophy of hepatocellular degeneration, necrosis and regeneration and liver inner tissue, cause liver structure disorder, distortion and quality hardening, the most effective stimulation body immune system opposing of hepatic insufficiency virus.Promote and adjust body's immunity, degraded liver cirrhosis disease collagen fiber are broken its helical structure, reach a large amount of outgrowth good efficacy of treatment because of hepatic necrosis and regenerating hepatic tissue.
Medicine of the present invention after concocting or handle according to the Pharmacopoeia of the People's Republic of China (1990 editions), directly is broken into the abundant mix homogeneously of powder before use.This medicated powder end is added the excipient adjuvant routinely and is made tablet and become pill, can become operational solid-state oral formulations.Medicine of the present invention also can be made into other dosage form.
With the 87 example treatments of medicine centering of the present invention, late period (losing the compensatory phase), liver cirrhosis disease patient (comprising posthepatitic cirrhosis, alcoholic cirrhosis, contain complication such as hepatic encephalopathy disease, upper gastrointestinal hemorrhage), Patients with Cirrhosis After Hepatitis 64 examples, the situation record of alcoholic cirrhosis patient 23 examples (wherein 26 examples esophagus fundus ventricularis varication occurs and break hemorrhagely, and 14 examples are with hepatic encephalopathy) is as follows:
1, check result before " two double " treatment
" two double " integrated mode: surface antigen positive, E-antigen positive, core antibody positive.(being commonly called as great three positive).
2, ultrasound diagnosis result:
1. not normal, the lobus dexter atrophy of liver, surface irregularity, edge indentation (or circle is blunt), in the liver echo obviously strengthen inhomogeneous, main portal vein broadening, portal vein left and right sides offshoot and trunk thromboembolism.
3, liver function test: albumin reduces, globulin raises, and albumin and globulin ratio are inverted, serum bilirubin 30-34 μ mol/L, and part is greater than 34 μ mol/L, and glutamate pyruvate transaminase and glutamic oxaloacetic transaminase, GOT raise.
4, above cirrhosis patients in decompensation (late period) disease patient treats January with medicine of the present invention (based on pill).Patients with Cirrhosis After Hepatitis " great three positive " changes surface antigen positive, E-antibody positive, core antibody positive (small three positive) into.Ultrasound diagnosis, the uneven joint joint shape that changes into of 73 routine liver surface, the edge becomes rough.15 routine ultrasound diagnosis change not quite in addition, and the portal vein embolization phenomenon partly is effectively controlled, and bleeding did not take place.12 examples hepatic encephalopathy do not occur and took place.Albumin raises, globulin reduces, serum bilirubin is reduced to below the 32 μ mol/L.
5, above patient is through Drug therapy of the present invention result's three months (course of treatment): patient's hepatitis B virus " great three positive ", change surface antigen positive, core antibody positive into.The liver table is by the uneven rough surface that changes into, and it is rough that the edge changes the edge into by zigzag.Albumin, globulin all are in normal value, and serum bilirubin is in normal value; Above-mentioned condition shows that posthepatitic cirrhosis disease patient virus replication is in and stops to duplicate or low-level replication status that the liver collagen fiber are effectively degraded, and the liver parenchyma reserve function recovers substantially.
Can affirm that thus it shows medicine of the present invention to posthepatitic cirrhosis disease, alcoholic cirrhosis disease curative effect: 1. nontoxic, have no side effect.2. improve and adjust body's immunity antiviral and fibrosis, recover liver reserve function.3. remove the blood vessel of intestinal bacteria, mediation obstruction, anti-hemorrhage and hepatic encephalopathy.
This shows that medicine of the present invention has significant superior curative effect for posthepatitic cirrhosis disease and alcoholic cirrhosis disease.Medicine of the present invention is applied widely.
The specific embodiment:
Medicine embodiment of the present invention sees Table 1:
Claims (3)
1, the medicine of treatment viral hepatitis, liver cirrhosis disease is characterized in that comprising by weight following component:
The Radix Ginseng Rubra 1～4
Mushroom 5～9
Ganoderma 3～8
Cordyceps 1～3
The Cortex Eucommiae 3～7
Oleum lini 6～10
2, the medicine of treatment viral hepatitis as claimed in claim 1, liver cirrhosis disease is characterized in that comprising by weight following component:
The Radix Ginseng Rubra 1～4
Mushroom 5～9
Ganoderma 3～8
Cordyceps 1～3
The Cortex Eucommiae 3～7
Oleum lini 6～10
Radix Scrophulariae 2～6
Fructus Jujubae 4～8
Huai wheat 5～10
Radix Glehniae 6～10
Colla Corii Asini 2～6
Ovum Gallus domesticus Flavus 2～5
Semen juglandis 6～10
Typhonium flagelliforme (Lodd.) Blume 1～5
Duck dried meat 6～12
3, the medicine of treatment viral hepatitis as claimed in claim 2, liver cirrhosis disease is characterized in that comprising by weight following component:
The Radix Ginseng Rubra 2
Dried mushroom 8
Ganoderma 4
Cordyceps 2
The Cortex Eucommiae 4
Oleum lini 8.5
Radix Scrophulariae 4
Fructus Jujubae 5
Huai wheat 8
Radix Glehniae 8
Colla Corii Asini 4
Ovum Gallus domesticus Flavus 3.5
Semen juglandis 8.5
Typhonium flagelliforme (Lodd.) Blume 2
Duck dried meat 10
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031354785A CN1481876A (en) | 2003-07-25 | 2003-07-25 | Medication for virus hepatitis and hepatocirrhosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031354785A CN1481876A (en) | 2003-07-25 | 2003-07-25 | Medication for virus hepatitis and hepatocirrhosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1481876A true CN1481876A (en) | 2004-03-17 |
Family
ID=34154654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031354785A Pending CN1481876A (en) | 2003-07-25 | 2003-07-25 | Medication for virus hepatitis and hepatocirrhosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1481876A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102068569A (en) * | 2010-09-16 | 2011-05-25 | 北京绿源求证科技发展有限责任公司 | Traditional Chinese medicine for treating cirrhosis |
| CN101843877B (en) * | 2009-09-25 | 2011-11-23 | 北京绿源求证科技发展有限责任公司 | Chinese medicament for treating liver cirrhosis |
| CN102824600A (en) * | 2012-08-20 | 2012-12-19 | 王三元 | Pure traditional Chinese medicine preparation for nourishing liver, protecting liver, softening liver and shrinking spleen and preparation method thereof |
| CN104069173A (en) * | 2014-07-15 | 2014-10-01 | 延边利孚生物科技有限公司 | Medicine composition for treating hepatic diseases and preparation method thereof |
| CN106309696A (en) * | 2016-08-31 | 2017-01-11 | 刘晓东 | Traditional Chinese medicine composition for treating hepatitis and liver cirrhosis |
-
2003
- 2003-07-25 CN CNA031354785A patent/CN1481876A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101843877B (en) * | 2009-09-25 | 2011-11-23 | 北京绿源求证科技发展有限责任公司 | Chinese medicament for treating liver cirrhosis |
| CN102068569A (en) * | 2010-09-16 | 2011-05-25 | 北京绿源求证科技发展有限责任公司 | Traditional Chinese medicine for treating cirrhosis |
| CN102824600A (en) * | 2012-08-20 | 2012-12-19 | 王三元 | Pure traditional Chinese medicine preparation for nourishing liver, protecting liver, softening liver and shrinking spleen and preparation method thereof |
| CN102824600B (en) * | 2012-08-20 | 2014-07-23 | 王三元 | Pure traditional Chinese medicine preparation for nourishing liver, protecting liver, softening liver and shrinking spleen and preparation method thereof |
| CN104069173A (en) * | 2014-07-15 | 2014-10-01 | 延边利孚生物科技有限公司 | Medicine composition for treating hepatic diseases and preparation method thereof |
| CN106309696A (en) * | 2016-08-31 | 2017-01-11 | 刘晓东 | Traditional Chinese medicine composition for treating hepatitis and liver cirrhosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1162171C (en) | Gynopathy treating traditional Chinese medicine | |
| CN1095674C (en) | Chinese medicinal composition for cerebrovascular disease, rheumatism and rheumatoid disease | |
| CN1692939A (en) | Traditional Chinese medicine pill for treating hepatitis B, and its prepn. method | |
| CN1283309C (en) | Pure medicinal liquor | |
| CN1481876A (en) | Medication for virus hepatitis and hepatocirrhosis | |
| CN1052889C (en) | Chinese proprietary for curing hepatitis | |
| CN1051471C (en) | A kind of pharmaceutical composition for treating osteoporosis | |
| CN1112194C (en) | Compound yexiazhu medicine and preparing process thereof | |
| CN1486736A (en) | A Chinese medicinal composition for treating hepatic fibrosis and liver cirrhosis, KANGJINRUANGGAN pill | |
| CN1294980C (en) | Medicine for treating liver disease | |
| CN1319587C (en) | Medicine powder for liver and spleen diseases | |
| CN1895619A (en) | Chinese-medicinal composition for preventing and treating liver disease and its preparation | |
| CN1059104C (en) | Capsule for anti hepatitis B | |
| CN107137455A (en) | A kind of pharmaceutical composition, preparation and purposes | |
| CN1186044C (en) | Chinese medicine 'lidandishi' for treating hepatobiliary calculus and cholecystitis | |
| CN100340286C (en) | Medicine for treating hepatitis B and its preparing process | |
| CN1059117C (en) | Katsutoxin pill for tumor and preparing method thereof | |
| CN1103796A (en) | Dressing medicine for treating hyperosteogeny and the prepn. method | |
| CN100515477C (en) | Chinese medicine decoction for treating prolapse of lumber intercertebtral disc | |
| CN1173718C (en) | Medicine for curing lupus erythematosus etc. immune diseases induced diseases | |
| CN1190229C (en) | Medicine for curing hepatitis B | |
| CN1650943A (en) | A drug for treating hypertension | |
| CN1235635C (en) | Medicine for treating osteosis | |
| CN1150015C (en) | Medicine for treating leucocytopenia caused by lupus erythematosus | |
| CN1281251C (en) | Medicine for treating chronic hepatitis and liver cirrhosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |